Aditxt, Inc. (NASDAQ:ADTX) Short Interest Up 102.9% in March

Aditxt, Inc. (NASDAQ:ADTX) was the target of a significant increase in short interest in the month of March. As of March 15th, there was short interest totalling 35,100 shares, an increase of 102.9% from the February 29th total of 17,300 shares. Based on an average daily volume of 570,800 shares, the short-interest ratio is presently 0.1 days. Approximately 1.8% of the shares of the company are sold short.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Virtu Financial LLC acquired a new position in Aditxt during the second quarter worth $71,000. Bank of New York Mellon Corp acquired a new position in Aditxt during the third quarter worth $119,000. Armistice Capital LLC acquired a new position in Aditxt during the third quarter worth $350,000. Finally, Schonfeld Strategic Advisors LLC acquired a new position in Aditxt during the third quarter worth $423,000. Institutional investors and hedge funds own 15.54% of the company’s stock.

Aditxt Price Performance

NASDAQ:ADTX opened at $3.40 on Friday. The stock’s 50 day simple moving average is $3.62 and its 200-day simple moving average is $6.32. Aditxt has a 12-month low of $2.95 and a 12-month high of $76.40.

About Aditxt

Aditxt, Inc, a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues.